Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis

Cancer Letters

Volumn 372, Issue 1, 2016, Pages 10-23

  Costantino, Valeria V ^a   Lobos Gonzalez, Lorena ^b   Ibañez, Jorge ^a   Fernandez, Dario ^a   Cuello Carrión, F Darío ^c   Valenzuela, Manuel A ^b   Barbieri, Manuel A ^d   Semino, Silvana N ^a   Jahn, Graciela A ^c   Quest, Andrew F G ^b   Lopez, Luis A ^a  

^a Instituto de Histologia y Embriologia   (Argentina)

^b UNIVERSITY OF CHILE   (Chile)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Apoptosis; Dehydroleucodine; Mathematical model; Melanoma; Premature senescence; Sesquiterpene lactones

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN D1; DEHYDROLEUCODINE; SESQUITERPENE LACTONE; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, MOUSE; CCNB1 PROTEIN, MOUSE; CCND1 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; LACTONE; REPRESSOR PROTEIN; SESQUITERPENE;

ANIMAL CELL; APOPTOSIS; ARTICLE; B16F0 CELL LINE; CANCER INHIBITION; CANCER MODEL; CELL COUNT; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; MALE; MATHEMATICAL MODEL; MELANOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL AGING; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INHIBITOR OF APOPTOSIS PROTEINS; LACTONES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; REPRESSOR PROTEINS; SESQUITERPENES; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN;

EID: 84958180313     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.004     Document Type: Article

References (61)

1. Taylor P.G., Dupuy Loo O.A., Bonilla J.A., Murillo R. Anticancer activities of two sesquiterpene lactones, millerenolide and thieleanin isolated from Viguiera sylvatica and Decachaeta thieleana. Fitoterapia 2008, 79:428-432.
2. Ghantous A., Gali-Muhtasib H., Vuorela H., Saliba N.A., Darwiche N. What made sesquiterpene lactones reach cancer clinical trials?. Drug Discov. Today 2010, 15:668-678.
3. Priestap H.A., Abboud K.A., Velandia A.E., Lopez L.A., Barbieri M.A. Dehydro-leucodin: a guaiane-type sesquiterpene lactone. Acta Crystallogr. Sect. E Struct. Rep. Online 2011, 67:o3470.
4. Giordano O.S., Guerreiro E., Pestchanker M.J., Guzman J., Pastor D., Guardia T. The gastric cytoprotective effect of several sesquiterpene lactones. J. Nat. Prod 1990, 53:803-809.
5. Costantino V.V., Mansilla S.F., Speroni J., Amaya C., Cuello-Carrion D., Ciocca D.R., et al. The sesquiterpene lactone dehydroleucodine triggers senescence and apoptosis in association with accumulation of DNA damage markers. PLoS ONE 2013, 8. e53168.
6. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., et al. Survivin, bcl-2, bax, and bcl-gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol 2003, 21:306-312.
7. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
8. Mouriaux F., Casagrande F., Pillaire M.J., Manenti S., Malecaze F., Darbon J.M. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest. Ophthalmol. Vis. Sci 1998, 39:876-884.
9. Gabri M.R., Mazorra Z., Ripoll G.V., Mesa C., Fernandez L.E., Gomez D.E., et al. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model. Clin. Cancer Res 2006, 12:7092-7098.
10. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9363-9367.
11. Lee B.Y., Han J.A., Im J.S., Morrone A., Johung K., Goodwin E.C., et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006, 5:187-195.
12. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 1976, 72:248-254.
13. Kim P.J., Plescia J., Clevers H., Fearon E.R., Altieri D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362:205-209.
14. Rodriguez D.A., Tapia J.C., Fernandez J.G., Torres V.A., Munoz N., Galleguillos D., et al. Caveolin-1-mediated suppression of cyclooxygenase-via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol. Biol. Cell 2009, 20:2297-2310.
15. Palladini A., Nicoletti G., Pappalardo F., Murgo A., Grosso V., Stivani V., et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res 2010, 70:7755-7763.
16. Cabrales L.E., Nava J.J., Aguilera A.R., Joa J.A., Ciria H.M., Gonzalez M.M., et al. Modified Gompertz equation for electrotherapy murine tumor growth kinetics: predictions and new hypotheses. BMC Cancer 2010, 10:589.
17. Vicencio J.M., Galluzzi L., Tajeddine N., Ortiz C., Criollo A., Tasdemir E., et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path-mini-review. Gerontology 2008, 54:92-99.
18. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
19. Ferguson B., Soyer H.P., Walker G.J. Clinicopathological characterization of mouse models of melanoma. Methods Mol. Biol 2015, 1267:251-261.
20. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
21. Denmeade S.R., Isaacs J.T. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol. Ther 2005, 4:14-22.
22. Cosme-Blanco W., Shen M.F., Lazar A.J., Pathak S., Lozano G., Multani A.S., et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007, 8:497-503.
23. Van N.T., Puebla-Osorio N., Pang H., Dujka M.E., Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J. Exp. Med 2007, 204:1453-1461.
24. Barboza J.A., Liu G., Ju Z., El-Naggar A.K., Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19842-19847.
25. Choudhury A.R., Ju Z., Djojosubroto M.W., Schienke A., Lechel A., Schaetzlein S., et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet 2007, 39:99-105.
26. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol 2007, 8:729-740.
27. Coppe J.P., Kauser K., Campisi J., Beausejour C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem 2006, 281:29568-29574.
28. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12072-12077.
29. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1:222-231.
30. Massague J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306.
31. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775-778.
32. Shao Z., Bao Q., Jiang F., Qian H., Fang Q., Hu X. VS-5584, a novel PI3K-mTOR dual inhibitor, inhibits melanoma cell growth in vitro and in vivo. PLoS ONE 2015, 10. e0132655.
33. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
34. Houben R., Becker J.C., Kappel A., Terheyden P., Brocker E.B., Goetz R., et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog 2004, 3:6.
35. Yang J., Zaja-Milatovic S., Thu Y.M., Lee F., Smykla R., Richmond A. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol. Cancer Ther 2009, 8:636-647.
36. Utikal J., Udart M., Leiter U., Peter R.U., Krahn G. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int. J. Oncol 2005, 26:597-605.
37. Daveri E., Valacchi G., Romagnoli R., Maellaro E., Maioli E. Antiproliferative effect of rottlerin on Sk-Mel-28 melanoma cells. Evid. Based Complement. Alternat. Med 2015, 2015:545838.
38. Kedinger V., Meulle A., Zounib O., Bonnet M.E., Gossart J.B., Benoit E., et al. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer 2013, 13:338.
39. Georgieva J., Sinha P., Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J. Clin. Pathol 2001, 54:229-235.
40. Ozeki M., Tamae D., Hou D.X., Wang T., Lebon T., Spitz D.R., et al. Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD. Anticancer Res 2004, 24:2657-2663.
41. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011, 10:35.
42. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
43. Azimi F., Scolyer R.A., Rumcheva P., Moncrieff M., Murali R., McCarthy S.W., et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol 2012, 30:2678-2683.
44. Rossi A.H., Farias A., Fernandez J.E., Bonomi H.R., Goldbaum F.A., Berguer P.M. Brucella spp. lumazine synthase induces a TLR4-mediated protective response against B16 melanoma in mice. PLoS ONE 2015, 10. e0126827.
45. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
46. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med 2005, 353:2654-2666.
47. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
48. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol 2004, 22:329-360.
49. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol 2006, 90:1-50.
50. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother 2012, 61:1019-1031.
51. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274:1664-1672.
52. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science 1994, 266:1821-1828.
53. Yang M.C., Choi S.U., Choi W.S., Kim S.Y., Lee K.R. Guaiane sesquiterpene lactones and amino acid-sesquiterpene lactone conjugates from the aerial parts of Saussurea pulchella. J. Nat. Prod 2008, 71:678-683.
54. Negrin G., Eiroa J.L., Morales M., Triana J., Quintana J., Estevez F. Naturally occurring asteriscunolide A induces apoptosis and activation of mitogen-activated protein kinase pathway in human tumor cell lines. Mol. Carcinog 2010, 49:488-499.
55. Lesiak K., Koprowska K., Zalesna I., Nejc D., Duchler M., Czyz M. Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. Melanoma Res 2010, 20:21-34.
56. Triana J., Eiroa J.L., Ortega J.J., Leon F., Brouard I., Torres F., et al. Sesquiterpene lactones from Gonospermum gomerae and G. fruticosum and their cytotoxic activities. J. Nat. Prod 2008, 71:2015-2020.
57. Arantes F.F., Barbosa L.C., Alvarenga E.S., Demuner A.J., Bezerra D.P., Ferreira J.R., et al. Synthesis and cytotoxic activity of alpha-santonin derivatives. Eur. J. Med. Chem 2009, 44:3739-3745.
58. Yan Y., Chou G.X., Hui W., Chu J.H., Fong W.F., Yu Z.L. Effects of sesquiterpenes isolated from largehead atractylodes rhizome on growth, migration, and differentiation of B16 melanoma cells. Integr. Cancer Ther 2011, 10:92-100.
59. Pratheeshkumar P., Kuttan G. Effect of vernolide-A, a sesquiterpene lactone from Vernonia cinerea L., on cell-mediated immune response in B16F-10 metastatic melanoma-bearing mice. Immunopharmacol. Immunotoxicol 2011, 33:533-538.
60. Kuttan G., Pratheeshkumar P., Manu K.A., Kuttan R. Inhibition of tumor progression by naturally occurring terpenoids. Pharm. Biol 2011, 49:995-1007.
61. Pratheeshkumar P., Kuttan G. Antimetastatic potential of vernolide-A, a sesquiterpenoid from Vernonia cinerea L. Hum. Exp. Toxicol 2012, 31:66-80.